| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 4th January 2021 | Jonathan Young | 2,960 | Open or private sale | $25.27 | $74,799.20 |
| 4th January 2021 | Jonathan Young | 100 | Open or private sale | $26.00 | $2,600.00 |
| 28th December 2020 | Andrew Cheng | 7,480 | Exercise of derivative | $0.62 | $4,637.60 |
| 21st December 2020 | Andrew Cheng | 10,500 | Exercise of derivative | $0.62 | $6,510.00 |
| 15th December 2020 | Andrew Cheng | 2,500 | Bona fide gift | $0.00 | |
| 11th December 2020 | Andrew Cheng | 50 | Bona fide gift | $0.00 | |
| 24th November 2020 | Tree Partners Iv, L.P. Apple | 375,000 | Open or private purchase | $39.00 | $14,625,000.00 |
| 24th November 2020 | Seth Loring Harrison | 375,000 | Open or private purchase | $39.00 | $14,625,000.00 |
| 23rd November 2020 | G. Walmsley Graham | 1,183,114 | Conversion of derivative | $0.00 | |
| 23rd November 2020 | G. Walmsley Graham | 1,400,761 | Conversion of derivative | $0.00 |
Akero Therapeutics
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases.
Ticker: AKRO
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 1744659
Employees: 13
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
We weren't able to import Fundamental data from the SEC disclosure.
There were no Red Flags found
Fundamentals
We weren't able to import Fundamental data from the SEC disclosure.
News
DXP Enterprises Reports Third Quarter 2020 Results
6th November 2020
17 Arrested For Running Fake Call Centre In Delhi: Police
6th November 2020
Ubiquiti Inc. Reports First Quarter Fiscal 2021 Financial Results
6th November 2020
